Nat Med Aug;15(8):871-2.

Transcription

1 1. Factors associated with virological response to etravirine in non nucleoside reverse transcriptase inhibitor experienced HIV-1 infected patients. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; the ANRS AC11 Resistance study group. Antimicrob Agents Chemother Nov High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group. Clin Infect Dis Nov 1;49(9): Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after longterm suppressive antiretroviral therapy in 236 patients. Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P, Seigneurin JM, Rouzioux C; ANRS AC11 Working Group. AIDS Oct 23;23(16): Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group. J Antimicrob Chemother Jul;64(1): Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S; ANRS CO5 HIV-2 Cohort Study Group. AIDS Jun 1;23(9): Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drugexperienced patients besides compensating for fitness loss. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich HG, Hance AJ, Clavel F; ANRS 109 Study Group. PLoS Pathog Mar;5(3):e The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun- Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C. J Virol May;83(10): Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. J Antimicrob Chemother Mar;63(3): A new human immunodeficiency virus derived from gorillas. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F.

2 Nat Med Aug;15(8): Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S. AIDS Jan 28;23(3): Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D; on behalf of the Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. AIDS Oct Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--anrs 111 trial. Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group. Fundam Clin Pharmacol Aug;23(4): Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group. J Antimicrob Chemother Sep;64(3): Predictive value of HIV-1 genotypic resistance test interpretation algorithms. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW. J Infect Dis Aug 1;200(3): Uncontrolled viral replication as a risk factor for non-aids severe clinical events in HIVinfected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, Strady C, Chêne G, Leport C, Moing VL; ANRS CO8 (APROCO-COPILOTE) Study Group. J Acquir Immune Defic Syndr Aug 1;51(4): Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F; COPHAR2-ANRS 111 Study Group. Eur J Clin Pharmacol Jul;65(7): Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, Villes V, Chêne G, Raffi F; ANRS CO8 APROCO-COPILOTE study group. AIDS May 15;23(8): Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Gut Jan;58(1): Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

3 Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F. Antivir Ther. 2009;14(6): , Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Klein I, Iung B, Labreuche J, Hess A, Wolff M, Messika-Zeitoun D, Lavallée P, Laissy JP, Leport C, Duval X; IMAGE Study Group. Stroke Nov;40(11): Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. AIDS Nov 13;23(17): Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Béthune MP, Peeters M, Woodfall B. Antivir Ther. 2009;14(5): Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. J Infect Dis Sep 15;200(6): Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S; FHDH-ANRS CO4 Clinical Epidemiology Group. AIDS Sep 24;23(15): Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X. Dis Colon Rectum Jun;52(6): Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over in France. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups. AIDS Mar 27;23(6): Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

4 Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis Apr 15;48(8): Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Clin Infect Dis Mar 1;48(5): Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. HIV Med Feb;10(2): How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates. Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D; Clinical Epidemiologic Group of the French Hospital Database on HIV (ANRS CO4 FHDH); Groupe d'etude Mortalité HIV Med Apr;10(4): Interleukine-2 therapy does not increase the risk of Hodgkin or non-hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. J Acquir Immune Defic Syndr Feb 1;50(2): Interruption of antiretroviral therapy is associated with increased plasma cystatin C. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group. AIDS Jan 2;23(1): Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, Fiévet MH, Boccara F, Bonnefont-Rousselot D, Melchior JC, Giral P, Costagliola D. AIDS Oct Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.

5 Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, Farinotti R, Gil S. Eur J Obstet Gynecol Reprod Biol Dec;147(2): Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient. Delaugerre C, Denis B, Peytavin G, Palmer P, Mourez T, Le Goff J, Molina JM, Simon F. J Clin Microbiol Nov;47(11): Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--anrs 111 trial. Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group. Fundam Clin Pharmacol Aug;23(4): Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM; EuroSIDA Study Group. Antivir Ther. 2009;14(1):75-83 Peytavin G. 39 Clinical pharmacokinetic of maraviroc] Med Mal Infect Mar;38 Suppl 1:S High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM. J Antimicrob Chemother Feb;63(2): Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Hirt D, Urien S, Ekouévi DK, Rey E, Arrivé E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone M, Leang SK, McIntyre J, Dabis F, Tréluyer JM; ANRS Clin Pharmacol Ther Feb;85(2): Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, Schneider V, Burgard M, Faye A, Mandelbrot L, Tubiana R, Rouzioux C; ANRS French Perinatal Cohort. Retrovirology Sep 19;6:85.

6 43 No relation between in-utero exposure to HAART and intrauterine growth retardation. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, Dollfus C, Rouzioux C, Blanche S, Warszawski J; ANRS French Perinatal Cohort. AIDS Jun 19;23(10): Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis Apr 15;48(8): Interleukine-2 therapy does not increase the risk of Hodgkin or non-hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. J Acquir Immune Defic Syndr Feb 1;50(2): Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort. Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, Blanche S, Tubiana R, Rouzioux C, Warszawski J; ANRS French Perinatal Cohort (EPF). Am J Obstet Gynecol Feb;200(2):160.e Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients. Landman R, Poupard M, Diallo M, Gueye NF, Diakhate N, Ndiaye B, Kane CT, Trylesinski A, Diop H, Mboup S, Fall MB, Deleporte E, Benalycherif AD, Girard PM, Sow PS. J Int Assoc Physicians AIDS Care (Chic Ill) Sep Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire. Spire B, Arnould B, Barbier F, Durant J, Gilquin J, Landman R, Carret S, Saussier C, El Kebir S, Cohen-Codar I. HIV Clin Trials Jul-Aug;10(4): Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

7 J Infect Dis Sep 15;200(6): HIV genetic diversity and its consequences.] Roquebert B, Damond F, Brun-Vézinet F, Descamps D. Pathol Biol (Paris) Mar;57(2):142-8.